Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease by Ayaka Hayashi, Ayaka Hayashi, Hiroto Ishihara, Mayuko Kawabe, Kazuhiko Kato, Kazuhiko Kato, Akio Nakashima, Akio Nakashima, Izumi Yamamoto, Teppei Sakano, Teppei Sakano, Hiroe Kobashi, Makoto Morita, Makoto Morita, Takashi Yokoo, Mitsuyoshi Urashima

Subjects: Get full text

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA... by Ruichen Gao, Wenjun Liang, Jintao Chen, Mingxia Yang, Xiaowei Yu, Xiaohua Wang

Subjects: Get full text

Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective... by Seok Jun Park, Seungwon Yang, Suhyun Lee, Sung Hwan Joo, Taemin Park, Dong Hyun Kim, Hyeonji Kim, Soyun Park, Jung-Tae Kim, Won Gun Kwack, Sung Wook Kang, Yun-Kyoung Song, Jae Myung Cha, Sang Youl Rhee, Eun Kyoung Chung

Subjects: “…immune checkpoint inhibitor…”
Get full text

Suppression of MCP-1, IFN-γ and IL-6 production of HNSCC ex vivo by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survival by Jana Wellhausen, Louisa Röhl, Michael Berszin, Irene Krücken, Irene Krücken, Veit Zebralla, Veit Zebralla, Markus Pirlich, Markus Pirlich, Matthaeus Stoehr, Matthaeus Stoehr, Susanne Wiegand, Susanne Wiegand, Susanne Wiegand, Andreas Dietz, Andreas Dietz, Theresa Wald, Theresa Wald, Gunnar Wichmann, Gunnar Wichmann

Subjects: “…PD-1:PD-L1 immune-checkpoint inhibitor (ICI) pembrolizumab…”
Get full text